Análise do setor de P&D farmacêutico no Brasil com base em depósitos de patentes e acordos de parceria em empresas públicas e privadas voltados à inovação de medicamentos
Loading...
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidade Federal de Juiz de Fora (UFJF)
Abstract
Pharmaceutical inputs form the foundation of the drug production chain, including
active ingredients, biological substances, excipients, and reagents. The 2022 supply
shortage crisis highlighted Brazil’s dependence on imported active pharmaceutical
ingredients, stimulating debates on strengthening research, development, and
innovation. Universities plays a key role in addressing infrastructure and technical
capacity limitations. This study analyzed the national R&D landscape for APIs through
patent filings and strategic partnerships. A total of 859 patent applications were
analyzed, correlating applicants’ countries of origin with national participation. The
highest concentrations were found on groups A61K 47 (211 records), A61K 31 (142),
C07K (131), and A61K 9 (129), all related to pharmaceutical or medical preparations.
Continuous participation of foreign companies, particularly from China, was observed
in the Brazilian pharmaceutical innovation landscape. Between 1997 and 2023,
national inventive activity increased, with 47 patent filings in the A61K, C07, and C12
domains, involving 37 applicants, predominantly higher education institutions. National
filings were mainly concentrated in subclasses A61K 31, A61K 9, and C12P. A
Patentscope search identified 106 pharmaceutical patents classified under subclass
A61P, primarily related to antineoplastic and anti-infective agents and treatments for
nervous system disorders. Patent WO2022061431, filed by UFRJ in co-ownership with
UFJF and INMETRO, stands out. Of the 112 filings analyzed, 65 involved universities,
24 pharmaceutical companies, 15 independent researchers, and 8 public companies.
In the second stage of the study, interviewees held managerial or technical analysis
positions, mostly with degrees in Pharmacy. Private companies were predominantly
large-sized, whereas public companies showed greater diversity. Regarding API
procurement, private companies prioritized direct purchasing, while public companies
mainly relied on public bidding processes. Half of the companies reported having a
dedicated R&D department. Public companies showed greater progress in research
on synthesis, semisynthesis, natural sources, and biomolecules compared to private
firms. One public and one private company did not believe that partnerships with
universities reduce labor and equipment costs. Except for funding allocated to
equipment acquisition reported by one public company, most firms were unaware of
government programs supporting technological development and innovation. Overall,
Brazil shows still incipient yet relevant progress in API research, development, and
innovation, largely driven by universities. Nevertheless, dependence on foreign
companies and limited national industrial participation persist, reinforcing the need for
integrated public policies to strengthen technological autonomy in APIs.
Description
Citation
Collections
Endorsement
Review
Supplemented By
Referenced By
Creative Commons license
Except where otherwise noted, this item's license is described as Acesso Aberto

